European Commission approval for Cosentyx as first and only IL-17A inhibitor for hidradenitis suppurativa – Novartis
Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an inadequate response to… read more.
